Valued at USD 3.13 billion in 2024, the gout therapeutics market is projected to reach USD 3.34 billion in 2025 and USD 6.15 billion by 2034, growing at a CAGR of 7.0% during the forecast period 2025–2034, according to Polaris Market Research. Gout is a form of inflammatory arthritis caused by uric acid crystal deposition. The gout therapeutics market comprises pharmaceutical products and treatment approaches that manage and alleviate symptoms, including urate-lowering therapies, anti-inflammatories, and novel biologics designed to prevent flare-ups and reduce uric acid levels.

Lifestyle Disorders Lift Gout Therapeutics Market Demand

Growing incidence of gout due to sedentary lifestyles, alcohol consumption, and obesity is driving demand for effective therapeutic options. People who consume purine-rich diets or have metabolic syndrome often experience elevated uric acid levels, leading to frequent and painful attacks. The report notes that rising hyperuricemia and gout prevalence is increasing demand for long-term therapeutic solutions.

Primary care physicians and specialists are increasingly recognizing the long-term impact of untreated hyperuricemia, prompting earlier diagnosis and intervention. Awareness campaigns by healthcare organizations and patient advocacy groups reinforce this trend and support broader adoption of prescription therapies over traditional self-medication.

Browse Insights:

https://www.polarismarketresearch.com/industry-analysis/gout-therapeutics-market

Chronic Gout Leads by Disease Condition

By disease condition, the market is segmented into acute gout and chronic gout. The chronic gout segment held the largest revenue share in 2024 owing to growing demand for long-term management therapies. Patients with recurrent flares and persistent hyperuricemia require continuous therapeutic intervention, and comorbidities such as kidney dysfunction and cardiovascular disease prompt multi-faceted treatment approaches.

Longer treatment duration, higher prescription frequency, and regular monitoring contribute to sustained revenue generation in chronic gout, while pharmaceutical innovation aimed at better controlling chronic manifestations supports robust sales.

Drug Class Dynamics: NSAIDs and Urate-Lowering Agents

By drug class, the market includes NSAIDs, corticosteroids, colchicine, urate-lowering agents, and others. The NSAIDs segment dominated in 2024 with about 43% of revenue, owing to rapid action in reducing inflammation and pain during acute flares. Physicians often prescribe NSAIDs as first-line treatment because of broad availability, a favorable short-term safety profile, and patient familiarity.

The urate-lowering agents segment is expected to register a significant CAGR from 2025 to 2034. These agents, including xanthine oxidase inhibitors and uricosurics, address the underlying cause of hyperuricemia rather than providing symptomatic relief alone. Ongoing research into novel urate-lowering agents with improved efficacy and reduced side effects is expected to accelerate uptake.

Demographic Drivers

Older adults are more likely to develop gout because of age-related metabolic changes, impaired kidney function, and multiple chronic diseases. According to the World Health Organization, about 16.7% of the global population will be aged 60 and older by 2030, and this group is projected to double to approximately 2.1 billion by 2050. The expanding geriatric population requires consistent management of uric acid levels alongside treatment for cardiovascular and renal complications, and developers are investing in patient-friendly formulations and lower-risk therapies tailored to the geriatric population.

Regional Insights and Key Players

North America accounted for about 50% of revenue in 2024, driven by strong healthcare infrastructure, early diagnosis, and widespread access to rheumatology care, with the US leading the region. Asia Pacific is expected to register the highest CAGR from 2025 to 2034, supported by rising awareness, better healthcare access, and increasing lifestyle-related hyperuricemia. China is growing rapidly owing to dietary changes, alcohol consumption, and an aging population.

Key players  Gout Therapeutics  include Arrowhead Pharmaceuticals, Inc.; AstraZeneca; Eisai Co., Ltd.; GSK plc.; Merck & Co., Inc.; Novartis AG; Regeneron Pharmaceuticals Inc.; Takeda Pharmaceutical Company Limited; Teijin Pharma Ltd.; and Zydus Group. In July 2025, Eisai launched “URECE” in China as a treatment for gout. Competitors rely on strategic alliances, joint ventures, and mergers and acquisitions to access drug candidates, while high costs of advanced therapies and limited reimbursement in emerging markets remain restraints.

More Trending Latest Reports By Polaris Market Research:

aquaculture-market

feed-mycotoxin-detoxifiers-market

acrylic-resins-market

gpu-server-market

earth-observation-small-satellite-market

trim-tabs-market

artificial-flowers-market

building-information-modeling-market

smart-pills-market

soybean-market